ethyl 1-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate | 629662-15-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 1-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate
• CAS: 629662-15-3
• 化学式: C₁₆H₁₈N₂O₂
• 分子量: 270.331
• InChiKey: WWAQHSLLVBIRRW-UHFFFAOYSA-N

物化性质

• 沸点：
  507.2±50.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate 、 3,4-二氟苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 ethyl 3-(3,4-difluorobenzoyl)-1-methyl-1,2,3,6-tetrahydro-azepino[4,5-b]indole-5-carboxylate
  参考文献：
  名称：

  Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

  摘要：

  Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.

  DOI：

  10.1021/jm8014124
• 作为产物：
  描述：

  3-(2-amino-1-methylethyl)indole hydrochloride 在 盐酸 作用下， 生成 ethyl 1-methyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate
  参考文献：
  名称：

  Azepinoindole derivatives as pharmaceutical agents

  摘要：

  提供了用于调节受体活性的化合物、组合物和方法。具体来说，提供了用于调节受体活性以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱症状的化合物和组合物。

  公开号：

  US20050054634A1

文献信息

• [EN] AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES D'AZEPINOINDOLE ET DE PYRIDOINDOLE UTILISES COMME AGENTS PHARMACEUTIQUES
  申请人：X CEPTOR THERAPEUTICS INC

  公开号：WO2003099821A1

  公开（公告）日：2003-12-04

  The present invention is directed to compounds of formula (I) and formula (II): formula (I) and (II), wherein R1-R8, A and n are as described in the description. These compounds are used in pharmaceutical compositions and methods for modulating the activity of orphan nuclear receptors.

  本发明涉及化合物的公式（I）和公式（II）：公式（I）和（II），其中R1-R8，A和n如描述中所述。这些化合物用于制备药物组合物，并用于调节孤儿核受体的活性的方法。
• Azepinoindole and pyridoindole derivatives as pharmaceutical agents
  申请人：X-Ceptor Therapeutics Inc.

  公开号：US20040023947A1

  公开（公告）日：2004-02-05

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性和治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或障碍症状的化合物和组合物。
• Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents
  申请人：Martin Richard

  公开号：US20090326218A1

  公开（公告）日：2009-12-31

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  本发明提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或缓解与受体活性直接或间接相关的一种或多种疾病或障碍的症状的方法。
• Azepine derivaties as pharmaceutical agents
  申请人：Martin Richard

  公开号：US20070015746A1

  公开（公告）日：2007-01-18

  Compounds, compositions and methods are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors.

  提供了化合物、组合物和方法，用于调节受体的活性，并用于治疗、预防或缓解与受体活性相关的一种或多种疾病或障碍的症状。
• Azepinoindole Derivatives As Pharmaceutical Agents
  申请人：Busch Brett

  公开号：US20100173824A1

  公开（公告）日：2010-07-08

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  本文提供了调节受体活性的化合物、组合物和方法。特别地，提供了用于调节受体活性以及治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或障碍症状的化合物和组合物。